Di Veroli C, Iugoli A R
Arch Sci Med (Torino). 1981 Jul-Sep;138(3):355-60.
The therapeutical efficacy and the tolerance of a long-range treatment with Aldatense were evaluated in 77 patients with essential hypertension. A standard treatment period of 120 days was set and the posology personalized (Aldatense 1 or 2 tablets/day) according to the therapeutical response observed at the controls carried out 1 week, 30, 60, 90 and 120 days from beginning treatment. The data obtained show that Aldatense exerts a strong anti-hypertension action; its effect is gradual and progressive and becomes chronically stable. The therapeutical index of the product proved good as the incidence of side effects was very low. In particular Aldatense did not interfere with blood potassium levels, glucides and purines metabolism and renal function.
对77例原发性高血压患者评估了阿尔达坦斯（Aldatense）长期治疗的疗效和耐受性。设定了120天的标准治疗期，并根据从开始治疗起1周、30天、60天、90天和120天进行的对照中观察到的治疗反应对剂量进行个性化调整（阿尔达坦斯1或2片/天）。获得的数据表明，阿尔达坦斯具有强大的抗高血压作用；其效果是渐进的，并且会长期稳定。该产品的治疗指数良好，因为副作用发生率非常低。特别是，阿尔达坦斯不影响血钾水平、糖类和嘌呤代谢以及肾功能。
